Peer-reviewed veterinary case report
Toceranib treatment results in some response for dogs
By Heishima, Kazuki et al.·Published in Journal of the American Animal Hospital Association·2018·From the Department of Veterinary Clinical Oncology (K.H., Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Short-Term Administration of Single-Agent Toceranib in Six Cases of Inoperable Massive Canine Hepatocellular Carcinoma.
- Species:
- dog
Plain-English summary
Six dogs with a type of liver cancer called hepatocellular carcinoma, which couldn't be surgically removed, were treated with a medication called toceranib. They took this medication every other day for at least two months. Out of the six dogs, three showed improvement, one had stable disease, and two continued to get worse. The dogs that responded well had lower liver enzyme levels, while those that didn’t respond still had high levels. This suggests that toceranib could be a helpful treatment for this type of cancer in dogs, but more research is needed.
People also search for: dog liver cancer treatment · toceranib for dogs · canine hepatocellular carcinoma symptoms
Abstract
Six dogs with massive hepatocellular carcinoma that was not amenable to surgery were treated by oral administration of single-agent toceranib at a dose of 2.0-3.0 mg/kg every other day for a minimum of 60 days. Partial response was achieved in three dogs, stable disease was achieved in one dog, and progressive disease occurred in two dogs, according to the canine Response Evaluation Criteria in Solid Tumors v1.0. Observed adverse events were mild to moderate in severity and reported in accordance with the Veterinary Cooperative Oncology Group's common terminology criteria for adverse events v1.1. Activities of alanine aminotransferase and alkaline phosphatase decreased in the cases that were sensitive to treatment with toceranib, whereas the activities remained high in resistant cases. Additionally, the level of phospho-vascular endothelial growth factor receptor 2 was found to be increased in a resistant case. Single-agent toceranib might prove to be an effective treatment for canine hepatocellular carcinoma pending further validation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30427710/